Click here to close now.


News Feed Item

Milestone Scientific Announces Financial Results for the Second Quarter of 2014

Revenue Increases 10.0% to $2.5 Million; Domestic Handpiece Sales Increase 22.0%; International Handpiece Sales Increase 20.1%; Domestic Sales Increase 9.3%; International Sales Increase 10.7%; Shareholders' Equity Increases to $15.3 Million

LIVINGSTON, NJ--(Marketwired - August 14, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced financial results and provided a business update for the three and six months ended June 30, 2014.

Leonard Osser, Chief Executive Officer of Milestone Scientific stated, "We are making progress advancing our epidural and intra-articular instruments through the regulatory process. We have developed a broad platform of computer-controlled injection technologies serving a wide array of medical applications and we look forward to announcing additional medical instruments later this year."

"We are also adding strategic resources that we believe will help us advance both our dental and medical instruments. We recently announced the appointment of Gian Domenico Trombetta as Chief Executive Officer of the dental division. He has an impressive track record leading high growth companies across a broad range of industries. We also announced the appointment as Marketing Consultant of Steven Robins, who has overseen the marketing and operations for billion dollar divisions of Fortune 500 healthcare and consumer product companies. Both executives bring valuable industry contracts and expertise."

Mr. Osser continued, "Total revenue for the second quarter of 2014 increased 10.0% to $2.5 million. We achieved a 22.0% increase in domestic handpiece sales and a 20.1% increase in international handpiece sales. This growth in domestic handpieces is due in part to the greater transparency we have with our customers, through our exclusive distributor Aseptico. We are able to establish direct relationships with the dentists and train them properly so they can utilize a greater number of handpieces per year."

"During the second quarter, we announced a $10 million financing which enables us to accelerate the development of additional medical instruments based on our patented CompuFlo and Dynamic Pressure Sensing technologies. Future medical applications of our technologies which will benefit from this investment could include colorectal surgery, podiatry, dermatology, orthopedics, nasal and sinus surgery, and cosmetic surgery, among others. The financing also allows us to more aggressively market and sell our dental instruments and handpieces in the United States and worldwide. As a result of this financing, we now have over $15 million of shareholders' equity. Given the strength of our balance sheet and continued positive cash flow from operations, we believe we are well positioned in the months and years ahead."

Revenue for the three months ended June 30, 2014 was $2.5 million versus $2.3 million for the second quarter of 2013. Domestic instrument sales decreased by $33,376 or 8.7% in the second quarter of 2014 versus the same period in 2013 due to lower distributor purchase prices for the STA instruments for a limited time period. The strategy is to facilitate the deployment of the STA instruments at a faster pace, thus generating recurring handpiece revenue. Domestic handpiece sales increased by $146,527, or 22.0% in 2014 over 2013. On the international front, instrument sales decreased by $34,677 or 9.4% in the second quarter of 2014 versus the same period in 2013. International handpiece sales increased by $162,758 or 20.1% in the second quarter of 2014 versus 2013. Gross profit for the second quarter of 2014 was $1.6 million or 63.6% of revenue versus $1.5 million or 67.3% of revenue for the second quarter of 2013. The decrease in gross margin reflected the lower pricing strategy on the instruments to drive handpiece sales. Operating income for the second quarter of 2014 was $47,507 versus an income of $151,113 for the second quarter of 2013. Net loss for the second quarter of 2014 was ($169,457), or $(0.01) per share, versus an income of $74,009 or $0.00 per share for the comparable period in 2013. Net loss for the second quarter of 2014 includes a Loss on Earnings from Medical Joint Venture of ($213,193) compared to ($47,093) for the three months ended June 30, 2013. Also, the June 30, 2013 net income included the positive impact of the reversal of the bad debt reserve for uncollectable accounts in 2013 that did not occur in 2014.

Revenue for the six months ended June 30, 2014 was $5.1 million versus $4.8 million for the six months ended June 30, 2013. In the domestic market, total revenue was approximately equal in both periods. On the international front, total revenue increased by $345,924 to $2.7 million versus $2.4 million for the same period in 2013. Gross profit for the six months ended June 30, 2014 was $3.3 million or 65.0% of revenue versus $3.2 million or 67.4% of revenue for the six months ended June 30, 2013. Operating income for the six months ended June 30, 2014 was $376,753 versus an income of $318,874 for the six months ended June 30, 2013. Net income for the six months ended June 30, 2014 was $25,377, or $0.00 per share, versus an income of $224,754, or $0.01 per share, for the comparable period in 2013. Net income for the six months ended June 30, 2014 includes a Loss on Earnings from Medical Joint Venture of ($343,716) compared to ($47,093) for the same period last year.

Milestone's executive management team will host a teleconference on Thursday, August 14, 2014 at 8:30 A.M. Eastern Time to discuss the company's financial results. 

The conference call will be available via telephone by dialing toll free 1-888-359-3627 and entering the pass code 8220117 or on the company's website at For those unable to participate at that time, a replay of the call will be archived on the company's website or can be accessed by dialing 1-888-203-1112 and entering the pass code 8220117. The replay will be available for 90 days.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website:

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

(tables follow)

                         MILESTONE SCIENTIFIC INC.                          
                     CONDENSED STATEMENTS OF OPERATIONS                     
                          Three Months Ended June    Six Months Ended June  
                                    30,                       30,           
                         ------------------------  ------------------------ 
                             2014         2013         2014         2013    
                         -----------  -----------  -----------  ----------- 
Product sales            $ 2,506,932  $ 2,278,235  $ 5,127,766  $ 4,767,778 
Cost of products sold        912,406      744,108    1,795,403    1,556,152 
                         -----------  -----------  -----------  ----------- 
  Gross profit             1,594,526    1,534,127    3,332,363    3,211,626 
                         -----------  -----------  -----------  ----------- 
Selling, general and                                                        
 administrative expenses   1,517,854    1,340,129    2,910,724    2,728,031 
Research and development                                                    
 expenses                     29,165       42,885       44,885      164,722 
                         -----------  -----------  -----------  ----------- 
Total operating expenses   1,547,019    1,383,014    2,955,609    2,892,752 
                         -----------  -----------  -----------  ----------- 
Income from operations        47,507      151,113      376,754      318,874 
Other income (expenses)                                                     
  Other income                     -            -            -       17,543 
  Interest income                                                           
   (expense)                     635      (30,011)         161      (64,569)
  Loss from Medical                                                         
   Joint Venture            (213,193)     (47,093)    (343,716)     (47,093)
  Loss from Education                                                       
   Joint Venture              (4,406)           -       (7,822)           - 
                         -----------  -----------  -----------  ----------- 
    Total other                                                             
     expenses, net          (216,964)     (77,104)    (351,377)     (94,119)
                         -----------  -----------  ===========  =========== 
Net (loss) income                                                           
 applicable to common                                                       
 stockholders            $  (169,457) $    74,009  $    25,377  $   224,754 
                         ===========  ===========  ===========  =========== 
Net (loss) income per                                                       
 share applicable to                                                        
 common stockholders -                                                      
  Basic                  $     (0.01) $      0.00  $      0.00  $      0.01 
                         ===========  ===========  ===========  =========== 
  Diluted                $     (0.01) $      0.00  $      0.00  $      0.01 
                         ===========  ===========  ===========  =========== 
Weighted average shares                                                     
 outstanding and to be                                                      
 issued -                                                                   
  Basic                   20,246,281   16,744,951   19,196,919   16,765,602 
                         ===========  ===========  ===========  =========== 
  Diluted                 20,246,281   17,056,219   22,206,942   17,124,936 
                         ===========  ===========  ===========  =========== 
                          MILESTONE SCIENTIFIC INC.                         
                          CONDENSED BALANCE SHEETS                          
                                                   June 30,    December 31, 
                                                     2014          2013     
                                                 ------------  ------------ 
Current Assets:                                                             
  Cash and cash equivalents                      $  1,121,721  $  1,147,198 
  Treasury Bills                                    9,498,498             - 
  Accounts receivable, net of allowance for                                 
   doubtful accounts of $5,000 as of June 30,                               
   2014 and $5,000 as of December 31, 2013          1,443,386     1,532,856 
  Inventories                                       1,964,390     1,321,652 
  Advances on contracts                             1,454,807       727,478 
  Prepaid expenses and other current assets           161,560       150,451 
                                                 ------------  ------------ 
    Total current assets                           15,644,362     4,879,635 
Advances on contracts                                 218,875     1,580,874 
Investment in Milestone Medical Inc                   760,750       924,115 
Investment in Milestone Education LLC                  34,261        42,082 
Furniture, Fixtures & Equipment net of                                      
 accumulated depreciation of $454,818 as of June                            
 30, 2014 and $476,884 as of December 31, 2013         38,153        23,988 
Patents, net of accumulated amortization of                                 
 $537,687 as of June 30, 2014 and $498,502 as of                            
 December 31, 2013                                    552,550       591,735 
Other assets                                           12,917        12,917 
                                                 ------------  ------------ 
      Total assets                               $ 17,261,868  $  8,055,346 
                                                 ============  ============ 
      LIABILITIES AND STOCKHOLDERS' EQUITY                                  
Current Liabilities:                                                        
  Accounts payable                               $    983,972  $  2,020,368 
  Customer advances                                   209,000             - 
  Accrued expenses and other payables                 754,538       515,133 
                                                 ------------  ------------ 
    Total current liabilities                       1,947,510     2,535,501 
                                                 ------------  ------------ 
Commitments and Contingencies                                               
Stockholders' Equity                                                        
  Series A Convertible Preferred Stock, par                                 
   value $.001, authorized 5,000,000 shares,                                
   7,000 and zero shares issued and outstanding,                            
   respectively                                  $          7  $          - 
  Common stock, par value $.001; authorized                                 
   50,000,000 shares; 21,074,786 shares issued                              
   875,322 shares to be issued and 21,041,453                               
   shares outstanding as of June 30, 2014;                                  
   17,759,540 shares issued, 1,839,930 shares to                            
   be issued, and 17,726,207 shares outstanding                             
   as of December 31, 2013                             21,949        19,599 
  Additional paid-in capital                       76,443,979    66,677,200 
  Accumulated deficit                             (60,240,061)  (60,265,438)
  Treasury stock, at cost, 33,333 shares             (911,516)     (911,516)
                                                 ------------  ------------ 
    Total stockholders' equity                     15,314,358     5,519,845 
                                                 ------------  ------------ 
      Total liabilities and stockholders' equity $ 17,261,868  $  8,055,346 
                                                 ============  ============ 

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Container technology is shaping the future of DevOps and it’s also changing the way organizations think about application development. With the rise of mobile applications in the enterprise, businesses are abandoning year-long development cycles and embracing technologies that enable rapid development and continuous deployment of apps. In his session at DevOps Summit, Kurt Collins, Developer Evangelist at, examined how Docker has evolved into a highly effective tool for application del...
Discussions of cloud computing have evolved in recent years from a focus on specific types of cloud, to a world of hybrid cloud, and to a world dominated by the APIs that make today's multi-cloud environments and hybrid clouds possible. In this Power Panel at 17th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the importance of customers being able to use the specific technologies they need, through environments and ecosystems that expose their APIs to make true ...
In recent years, at least 40% of companies using cloud applications have experienced data loss. One of the best prevention against cloud data loss is backing up your cloud data. In his General Session at 17th Cloud Expo, Sam McIntyre, Partner Enablement Specialist at eFolder, presented how organizations can use eFolder Cloudfinder to automate backups of cloud application data. He also demonstrated how easy it is to search and restore cloud application data using Cloudfinder.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York and Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty ...
Internet of @ThingsExpo, taking place June 7-9, 2016 at Javits Center, New York City and Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 18th International @CloudExpo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo New York Call for Papers is now open.
The cloud. Like a comic book superhero, there seems to be no problem it can’t fix or cost it can’t slash. Yet making the transition is not always easy and production environments are still largely on premise. Taking some practical and sensible steps to reduce risk can also help provide a basis for a successful cloud transition. A plethora of surveys from the likes of IDG and Gartner show that more than 70 percent of enterprises have deployed at least one or more cloud application or workload. Y...
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
Growth hacking is common for startups to make unheard-of progress in building their business. Career Hacks can help Geek Girls and those who support them (yes, that's you too, Dad!) to excel in this typically male-dominated world. Get ready to learn the facts: Is there a bias against women in the tech / developer communities? Why are women 50% of the workforce, but hold only 24% of the STEM or IT positions? Some beginnings of what to do about it! In her Day 2 Keynote at 17th Cloud Expo, San...
As organizations shift towards IT-as-a-service models, the need for managing & protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection & E-Discovery of your data - whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise.
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
In his General Session at DevOps Summit, Asaf Yigal, Co-Founder & VP of Product at, explored the value of Kibana 4 for log analysis and provided a hands-on tutorial on how to set up Kibana 4 and get the most out of Apache log files. He examined three use cases: IT operations, business intelligence, and security and compliance. Asaf Yigal is co-founder and VP of Product at log analytics software company In the past, he was co-founder of social-trading platform Currensee, which...
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, explored the IoT cloud-based platform technologies driving t...
There are over 120 breakout sessions in all, with Keynotes, General Sessions, and Power Panels adding to three days of incredibly rich presentations and content. Join @ThingsExpo conference chair Roger Strukhoff (@IoT2040), June 7-9, 2016 in New York City, for three days of intense 'Internet of Things' discussion and focus, including Big Data's indespensable role in IoT, Smart Grids and Industrial Internet of Things, Wearables and Consumer IoT, as well as (new) IoT's use in Vertical Markets.
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.